FY12-13 Interim Results Presentation

(6 Months Ended 30th Sep 2012)

2

Data and information contained in this presentation is provided for informational purposes only. GoldenMeditech Holdings Limited takes no liabilities for any errors or delays in the content, or for any actionstaken in reliance thereon.

This presentation and subsequent discussions may contain forward-looking statements that are basedon the current beliefs, assumptions, expectations, estimates, and projections of the management ofGolden Meditech Holdings Limited about its businesses and the industries and markets in which itoperates. These forward-looking statements include, without limitation, statements relating to revenues,earnings and stock performance. The words “believe”, “intend”, “expect”, “anticipate”, “project”,“estimate”, “predict” and similar expressions are also intended to identify the forward-looking statements.These statements are not guarantees of future performance and are subject to various risks anduncertainties, including, but not limited to, changes in legal, financial and regulatory frameworks, actualdemand, exchange rate fluctuations, market shares, competition, environmental risks, internationaleconomic and financial market conditions, project approval, cost estimates and other risks, which arebeyond the control of Golden Meditech Holdings Limited and are difficult to predict. Consequently, futurefinancial results could differ materially from those expressed or forecasted in the forward-lookingstatements.

Disclaimer

3

Company Profile

Healthcare Services Segment

• GM Hospital Group (“GMHG”) consists:

• New 600-bed hospital in Beijing (to be operational by end of FY12/13)- specialized in haematology and expatriates market in Beijing

• Shanghai Daopei Hospitals - one of largest haematology hospitals in China

• Shanghai East International Medical Centre (“SEIMC”), branded international hospital provides premium healthcare services in vicinity of Shanghai

• Pioneering medical insurance administration solutions provider in China, GM-Medicare (China) Company Ltd. (“GM-Medicare”)

• Founding and largest shareholder of China Cord Blood Corporation (“CCBC”), largest cord blood bank operator in China

Medical Devices Segment• Leading medical devices manufacturer in China - Beijing Jingjing Medical Equipment Co., Ltd.

(“BJJJ”)

Golden Meditech Holdings Limited - leading integrated healthcare enterprise which focuses on China’s

healthcare industry. Core operations are categorized into two segments:

Golden Meditech

(801.HK; 910801.TW)

Medical Devices

Segment

Healthcare Services

Segment

China Cord Blood

Corporation

(NYSE: CO) GM Hospital Group

GM-Medicare Management (China)

Co., Ltd.

Strategic Investment

Fortress Group Limited

(formerly known as FunTalk China)

Chinese Herbal Medicine Business

Business Structure

4

NB: Entities highlighted in BLUE represents publicly-listed entities.

1H-FY12/13 Highlights

• Turnover �6.4% to HK$224,464,000, growth amid complicated market conditions

• Revenue from Healthcare Services Segment remained steady at HK$71,670,000, slowed down by strategic relocation of

hospital in Beijing, new hospital is scheduled to be operational by end of FY12/13

• Medical Devices Segment posted solid performance, �6.6% to HK$140,649,000 in revenue, launch of new government

healthcare policies expect to drive sales forward

• CCBC contributed HK$30,120,000, increased 1.3% due to accounting treatment for non-cash items associated with issuance

of Convertible Notes to KKR

• Profit Attributable to Shareholders �11.2% to HK$85,255,000, however, Adjusted Profit Attributable to Shareholders �

63.6% * to HK$30,363,000 exclude gain from fair value changes of financial assets and financial liabilities

• Interim EPS : 4.23 HK cents, no interim dividend declared

5

• Major Developments:

– Group increased stakes in GMHG through acquiring Convertible Notes from New Horizon to consolidate interest in

existing hospital management business. In return, New Horizon received 279,344,444 new shares at issue price of

HK$0.9 per share

– New hospital pending for opening by end of FY12/13

– Invested US$50 mm in CCBC through subscribing 7% Convertible Notes due 2017

– Increased shareholding in medical devices division, China Bright to 95.1% to capture opportunities arising from

favourable Chinese policies on blood transfusion and extended separate listing by 18 months until February 2014

– Signed agreement with ThermoGenesis (NASDAQ: KOOL) to distribute AXP® AutoXpress® System to develop

new revenue stream

* Excluding non-cash and non-operating gain of HK$54,892,000, due to fair value changes of financial assets and financial liabilities

6

1H-FY12/13 Results Summary

HK$ 1H12/13 1H11/12 % Change

Turnover

Hospital Management Service Income

Medical Insurance Administration Service Income

Medical Devices Sales

Medical Accessories Sales

Chinese Herbal Medicine Sales

71,173,000

497,000

83,432,000

57,217,000

12,145,000

62,747,000

379,000

81,900,000

49,994,000

15,862,000

13.4%

31.1%

1.9%

14.4%

(23.4%)224,464,000 210,882,000 6.4%

Share of Profit from Associates

China Cord Blood Corporation (“CCBC,” CO:US)

China National Medical Equipment Industry Corp. (CMIC)

Fortress Group Limited (Formerly FunTalk China)

30,120,000

1,608,000

24,435,000

29,728,000

2,272,000

40,094,000

1.3%

(29.2%)

(39.1%)

Profit After Tax 96,903,000 84,425,000 14.8%

Profit Attributable to Shareholders 85,255,000 76,645,000 11.2%

Adjusted Profit Attributable to Shareholders* 30,363,000 83,518,000 (63.6%)

Earnings Per Share (Basic) 4.23 HK cents 3.93 HK Cents 7.6%

Adjusted Earnings Per Share (Basic)# 1.51 HK cents 4.28 HK cents (64.7%)

*Excluding non-cash and non-operating gain of HK$54,892,000 (6 months ended 30 September 2011: non-cash and non-operating

loss of HK$41,526,000) due to fair value changes of financial assets and financial liabilities; and excluding gain on partial disposal

of an associate of HK$34,653,000 recorded in the 6 months ended 30 September 2011# Based on Adjusted Profit Attributable to Shareholders

7

Strong Balance Sheet

HK$ ‘000 IR12/13 FY11/12

Total NAV per share (HK$) 1.95 2.04

Total Assets 6,781,331 6,979,375

Total Assets less Current Liabilities 5,716,440 5,393,986

Total Equity Attributable to Shareholders of the Company 4,432,307 4,060,009

Cash and bank balances 410,430 819,963

Gearing ratio 14.3% 24.5%

• Cash and bank deposits amounted to HK$410.4 mm (FY11/12: HK$820.0 mm); total interest

bearing debt stood at HK$227.3 mm (FY11/12: HK$653.9 mm); share repurchase obligations

and other liabilities associated with it totalled HK$517.7 mm (FY11/12: HK$554.2 mm)

• Satisfactory financial position with sufficient capital and financial resources to meet future

business development needs

• Hospital Management Business revenue was HK$71,173,000, flat revenue growth resulted from

temporary suspension of Daopei Beijing pending for relocation to new hospital facility

• New hospital in Beijing is scheduled to be operational by end of FY12/13. New facility will host

600-bed over floor area of 74,035 m2

• Group increased ownership in GMHG through acquiring Convertible Notes from New Horizon to

fortify interest in hospital management businesses

• Invested US$50 mm in CCBC by acquiring Convertible Notes

8

Highlights of Healthcare Services Segment

Building Sustainable Platforms for Healthcare Services Segment

Healthcare Services

(HK$ mm)

CCBC contribution as

affiliate - deconsolidated

9Artist’s impressions of proposed designs for new hospital in Beijing only

Highlight of GM Hospital Group

• New hospital facility in Beijing’s Haidian District to be operational by 2H FY12/13, Daopei Beijing

will be strategically relocated to new hospital

• Site area approx. 18,692 m2; permissible construction area of 74,035 m2

• New facility with larger floor areas, more beds and increased range of services to address

patients’ different needs is expected to contribute higher revenue

• GM-Medicare Management (China) Co., Ltd., a pioneering specialist in medical insurance

administration solutions provider

• Established in April 2010, to develop missing link between insured, insurance companies

and local governments

• Building advanced IT infrastructure tailor-made for China market, to meet demands of

various health insurance operators

• Operating performance in line with management expectations since inception

10

Highlights of Service Business

Medical Insurance Administration Business

• CCBC (CO.US) posted impressive growth and contributed HK$30.1 mm

• Group invested US$50 mm into CCBC in September 2012 through subscribing 7% Convertible Notes

due 2017

• Highlights of CCBC’s results 1H FY2013:

– Revenue increased by 31.1% to RMB243.8 mm from RMB185.9 mm

– New subscriber sign-ups reached 34,951

– Operating income increased by 33.5% to RMB91.4 mm from RMB68.5 mm

– Net income attributable to shareholders was RMB55.8 mm, affected by non-cash accounting treatment for

derivatives associated with financial instruments of convertible notes issued to KKR investment fund in April 2012,

contribution to Golden Meditech increased1.3% to HK$30.1 mm

– Operating cash flow amounted to RMB279.4 mm

– Share swap with Cordlife Group (P8A.SGX) to form strategic alliances with Cordlife to develop China and Asia

Pacific markets

11

Highlights of Service Business

Highlights of Medical Devices Segment

12

• Revenue up 6.6% to HK$140,649,000, mostly attributable to increase in device utilization

• The segment accounted for 62.7% of Group’s total revenue, with medical devices sales accounted for

59.3% and medical accessories sales accounted for 40.7% of segmental revenue respectively

• Implementation of the MOH’s “Level III General Hospital Accreditation and Administration Standards”,

(三級綜合醫院評審標準) allows hospital managers to initiate autologous blood recovery programmes to

alleviate surgical blood shortages

• Group Increased stake in medical devices division, China Bright to 95.1% and extend separate listing of

China Bright by 18 months till February 2014

• Leverage on existing network to expand new revenue stream by entering into distribution agreement for

overseas products such as ThemoGenesis

Solid Performance and Return

Medical Devices

(HK$ ‘000)Strategic Price Cut

Strategic Investments

• Currently holds two strategic investments

– 29.4% stake in Fortress Group (special private vehicle which privatized formerlyNASDAQ-listed FunTalk China Holdings Limited in August 2011)

– 100% shareholding in Chinese herbal medicine business

• Revenue from FunTalk business was down by 13.8%, compared with H-o-H. Profits fromFortress was down by 39.1% to HK$24,435,000 due to non-cash expenses associated withfinancial liabilities

• Chinese herbal medicine business reported loss of HK$16,531,000, below managementexpectations

• Consider disposals of non-strategic divisions at appropriate time to focus on enhancingcore healthcare business and any proceeds raised will be allocated among existingbusinesses, and shareholders

13

14

Company Outlook

• Cord blood bank to further increase market penetration in Beijing,Guangdong and Zhejiang

• New hospital operation is expected to contribute good source of income toGroup

• GM-Medicare, new medical insurance claim processing BPO to capturesignificant unaddressed demands to capture prospective demand in China

Healthcare Services Segment:

• Efficiently promote new strategies for device sales to lower tier hospitals

• Drive for growth in accessories sales

• Develop distribution of imported medical devices

Medical device segment:

15

Investor Relations Department

Email: ir@goldenmeditech.com

Tel: +852 3605 8180

Website: www.goldenmeditech.com